Free Trial

argenex (ARGX) Stock Forecast & Price Target

argenex logo
$761.44 -6.56 (-0.85%)
As of 10:12 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

argenex - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
0
Buy
23

Based on 23 Wall Street analysts who have issued ratings for argenex in the last 12 months, the stock has a consensus rating of "Buy." Out of the 23 analysts, 21 have given a buy rating, and 2 have given a strong buy rating for ARGX.

Consensus Price Target

$772.84
1.50% Upside
According to the 23 analysts' twelve-month price targets for argenex, the average price target is $772.84. The highest price target for ARGX is $1,070.00, while the lowest price target for ARGX is $605.00. The average price target represents a forecasted upside of 1.50% from the current price of $761.44.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenex and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARGX Analyst Ratings Over Time

TypeCurrent Forecast
9/9/24 to 9/9/25
1 Month Ago
8/10/24 to 8/10/25
3 Months Ago
6/11/24 to 6/11/25
1 Year Ago
9/10/23 to 9/9/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
21 Buy rating(s)
18 Buy rating(s)
19 Buy rating(s)
18 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$772.84$746.81$709.18$547.74
Forecasted Upside1.50% Upside12.84% Upside23.34% Upside-0.87% Downside
Consensus RatingBuyBuyBuyModerate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenex Stock vs. The Competition

TypeargenexMedical CompaniesS&P 500
Consensus Rating Score
3.09
2.78
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside0.63% Upside17,284.25% Upside10.50% Upside
News Sentiment Rating
Positive News

See Recent ARGX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/2/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Tazeen Ahmad
Not Rated
Boost TargetBuy$880.00 ➝ $887.00+25.76%
8/26/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set TargetBuy$818.00+16.11%
8/26/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Allison Bratzel
Allison Bratzel
Not Rated
Boost TargetOverweight$750.00 ➝ $820.00+17.27%
8/25/2025Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$800.00+15.51%
8/25/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$850.00+28.79%
8/4/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$775.00 ➝ $830.00+22.16%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$700.00 ➝ $766.00+14.71%
8/1/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$1,060.00 ➝ $1,070.00+60.24%
8/1/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$720.00 ➝ $774.00+15.47%
7/31/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$741.00 ➝ $756.00+12.78%
7/8/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy
5/21/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
5/14/2025JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$699.00+30.93%
5/13/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
5/13/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$680.00 ➝ $680.00+21.23%
5/9/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$704.00 ➝ $708.00+27.59%
3/17/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform
2/28/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
1/14/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$660.00 ➝ $700.00+3.93%
11/21/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$675.00 ➝ $706.00+19.29%
11/12/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer PerformOutperform$697.00+18.35%
11/5/2024Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector PerformSector Outperform$439.00 ➝ $715.00+21.46%
10/10/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$605.00+16.23%
8/6/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight
6/24/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$485.00 ➝ $500.00+14.82%
12/12/2023TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$612.00 ➝ $641.00+41.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:12 AM ET.


Should I Buy argenex Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 7, 2025. Please send any questions or comments about these argenex pros and cons to contact@marketbeat.com.

argenex
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in argenx SE:

  • The current stock price is around $733.66, reflecting strong market interest and potential for growth.
  • Institutional investors and hedge funds own over 60% of the company's stock, indicating confidence from major financial players.
  • Recent analyst upgrades have raised price targets significantly, with some analysts projecting targets above $800, suggesting strong future performance.
  • argenx SE is actively developing innovative therapies for various autoimmune diseases, which could lead to substantial revenue growth if successful.
  • The company has a robust pipeline, including its lead product candidate, efgartigimod, which is aimed at treating multiple serious conditions.

argenex
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in argenx SE for these reasons:

  • Despite recent gains, the stock has experienced volatility, which may pose risks for investors seeking stability.
  • High valuation metrics, such as a P/E ratio of 37.62, could indicate that the stock is overvalued compared to its earnings potential.
  • Dependence on the success of its lead product candidate means that any setbacks in clinical trials could negatively impact stock performance.
  • Market competition in the biotechnology sector is fierce, which could hinder argenx SE's ability to capture market share.
  • Recent reductions in positions by some institutional investors may signal caution regarding the stock's future performance.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for argenex is $772.84, with a high forecast of $1,070.00 and a low forecast of $605.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenex in the last twelve months. There are currently 21 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares.

According to analysts, argenex's stock has a predicted upside of 1.50% based on their 12-month stock forecasts.

Over the previous 90 days, argenex's stock had 1 upgrade by analysts.

Analysts like argenex more than other "medical" companies. The consensus rating for argenex is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARGX compares to other companies.


This page (NASDAQ:ARGX) was last updated on 9/9/2025 by MarketBeat.com Staff
From Our Partners